Share Email Print

Proceedings Paper

International registry results for an interstitial laser BPH treatment device
Author(s): Richard L. Conn; Rolf Muschter M.D.; Curtis S. Adams; Victor C. Esch
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Benign prostatic hyperplasia (BPH) can significantly impair quality of life in older men. Most men over 60 experience some symptoms due to BPH and it is thought that essentially all men would eventually be affected by it if they lived long enough. At present, transurethral resection of the prostate (TURP), a surgical treatment for BPH, is one of the more common procedures performed in the developed world, particularly in the United States. A number of other treatments are also often used, including open prostatectomy, side-firing lasers, and drug therapy. With the population in the developed world rapidly aging, BPH is expected to affect an even larger group of men in the future. Current methods of therapy carry significant disadvantages. Open prostatectomy carries a fairly high risk of impotence and incontinence, as well as sometimes significant risk of death depending on the patient's age and medical conditions. TURP also carries similar risks, albeit reduced, including the risk of substantial blood loss and a small but meaningful risk of death. Side-firing lasers are thought to have a reduced risk of death compared to TURP due to significantly reduced bleeding; however, patients often experience an extended period of pain during voiding due to prolonged tissue sloughing. Drug treatment, although useful for some patients, does not strongly improve symptoms in the majority of patients. Even with the current range of treatments, many patients with symptomatic BPH elect to avoid any current treatment due to risks and side effects. As a possible solution to this problem, previous writers have suggested the possibility of treating BPH through interstitial thermotherapy. In this treatment, prostatic tissue is heated from within the prostate to the point of irreversible necrosis. Healing processes then reduce the volume of the affected tissue, even in the absence of sloughing. This study covers initial human use of such a device, using an 810 nm wavelength diode laser not previously used for such therapy.

Paper Details

Date Published: 17 May 1996
PDF: 5 pages
Proc. SPIE 2671, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VI, (17 May 1996); doi: 10.1117/12.240023
Show Author Affiliations
Richard L. Conn, Lovelace Health Systems (United States)
Rolf Muschter M.D., Lovelace Health Systems (United States)
Curtis S. Adams, Lovelace Health Systems (United States)
Victor C. Esch, Lovelace Health Systems (United States)

Published in SPIE Proceedings Vol. 2671:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VI
C. Thomas Vangsness M.D.; Kenneth Eugene Bartels D.V.M.; Lawrence S. Bass M.D.; Graham M. Watson M.D.; R. Rox Anderson M.D.; R. Rox Anderson M.D.; Royice B. Everett; Douglas E. Ott M.D.; Reza S. Malek M.D.; Rodney A. White M.D.; Lloyd P. Tate V.D.M.; Aaron P. Perlmutter M.D., Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?